BioFinlandin jäsen

Anison Therapeutics aims at building a portfolio of technologies targeting the Human Papillomavirus(HPV)-mediated diseases.

The first steps are taken by dedicated efforts towards developing and commercializing a topical cream (containing a HPV targeting compound) that addresses unmet medical needs for genital warts, with preclinical studies projected to start during the first half of 2023. Longer term, the company will also focus on the treatment of genital pre-cancerous lesions and other HPV-associated warts, including common and foot(plantar) warts, thus becoming a successful company with solid sales growth and a strong pipeline of new products to be introduced to the roughly >$8Bn market.